Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 18 of 18 for “"Cancer drug development"”.
-
An analytics approach to designing clinical trials for cancer
Since chemotherapy began as a treatment for cancer in the 1940s, cancer drug development has become a multi-billion dollar industry. Combination chemotherapy remains the leading treatment for advanced cancers, and cancer drug research and clinical trials are enormous expenses for pharmaceutical …
-
Towards Refinement for Measuring Subcutaneously Transplanted Tumour Models in Mice
… subcutaneous tumour models is a key process in cancer drug development. Tumour material is implanted subcutaneously and tumour growth measured using callipers. However this methodology can have poor reproducibility and accuracy due to observer variation. Furthermore the physical pressure of …
-
Towards Refinement for Measuring Subcutaneously Transplanted Tumour Models in Mice
… subcutaneous tumour models is a key process in cancer drug development. Tumour material is implanted subcutaneously and tumour growth measured using callipers. However this methodology can have poor reproducibility and accuracy due to observer variation. Furthermore the physical pressure of …
-
Development of in vivo tumour models for non-invasive proof-of-principle investigation of novel therapeutic agents. Engineering and characterisation of bioluminescent cell reporter systems for in vivo analysis of anti-cancer therapy pharmacodynamics.
Despite significant advances in cancer treatment, clinical response remains suboptimal and there is a continued requirement for improved chemotherapeutics. The attrition rate for new therapies is high, due principally to lack of in vivo efficacy and poor pharmacodynamics. Consequently better …
-
Insights into the role of PFKFB3 in cancer
… isoform of PFK-2, which is highly expressed in cancer cells, has been suggested to be associated with enhanced aerobic glycolysis in cancer by elevating the intracellular levels of key glycolytic activator, Fru-2,6-P2. This work describes the importance of PFKFB3 function in metabolic …
-
Characterisation of non-essential genes required for survival under conditions of DNA stress
Genomic instability is a hallmark of cancer. Cancer progression depends on the development and amplification of mutations that alter the cellular response to threats to the genome. This can lead to DNA replication stress and the potential loss of genetic integrity of the newly formed cells. The …
-
Systems level characterizations of single and combination drug mechanisms of action in vitro and in vivo
… characterization is a critical limiting step in cancer drug development. At the present time, high throughput screens of natural products and combinatorial synthesis libraries generate more pharmaceutical leads than can be characterized in detail. Lead optimization further generates many …
-
Identification and Development of Novel Compounds for the Treatment of Human Cancers
… some progress has been made in the treatment of cancer over the last sixty years, the majority of chemotherapeutics has fallen short. Because general chemotherapies that target DNA replication have only a limited efficacy and significant non-target side-effects, a new paradigm for cancer drug …
-
Proteomic Profiling of Pro and Active Matrix Metalloproteinases using Tandem Mass Spectrometry. Optimization of Affinity Chromatography and nHPLC-MALDI-MS/MS for Proteomic discrimination of Matrix Metalloproteinases in pre-clinical Cancer Model.
… in biological samples. Moreover, MMP-based anti-cancer drug development has also been challenged because, currently, there is no robust methodology to distinguish the inactive pro-enzymes, active enzymes or those complexed with endogenous inhibitors in biological specimens. The objective of this …
-
Characterisation of STRO-1 expression on human mesenchymal stem cells and identification of putative cancer stem cells in osteosarcoma: prevention by micronutrients
… ultimately led to the identification of putative cancer stem cells (CSCs) in seven osteosarcoma cell lines initially based on STRO-1 expression. With MG-63 strongly expressing STRO-1, the maintenance of MSC-like properties by STRO-1 expressing cell lines was investigated. A heterogeneous pattern …
-
A Molecular and In Vivo Investigation of Advanced Prostate Cancer: Deconstructing Ampk Activity and Developing An Improved Mouse Model
<p>Prostate cancer is one of the leading causes of cancer-related death in men. Prostate cancer is dependent on androgen receptor (AR)-mediated pathways, and AR is therefore targeted to treat advanced prostate cancer. Despite an initial response to current AR-targeted therapies, patients invariably …
-
Mathematical Imaging Tools in Cancer Research - From Mitosis Analysis to Sparse Regularisation
… deals with customised image analysis tools in cancer research. In the field of biomedical sciences, mathematical imaging has become crucial in order to account for advancements in technical equipment and data storage by sound mathematical methods that can process and analyse imaging data in an …
-
Development Of Elisa-Based Hdac Activity Assay For Identification Of Isoform Selective Hdac Inhibitors
<p>Cancers are one of the leading causes of death in United States, effecting roughly 20% of the population. To develop effective anti-cancer agents, vast research is in progress that targets various factors leading to cancer. One such area of cancer research is developing drugs that inhibit …
-
Bayesian Semi-Mechanistic Dose-Finding Designs For Phase I Oncology Trials
… and efficient in evaluating an experimental drug. In oncology, despite the great advances in novel dose-finding designs, the high failure rates of clinical cancer drug development from phase I to III trials call for further improvements on novel designs, in addition to the need to promote and …
-
An evaluation of cancer biomarkers in normal ovarian epithelial cells and ovarian cancer cell lines
… are over 190,000 new reported cases of ovarian cancers per annum. This comprises 3% to 4% of all cancers in women. Ovarian cancer is one of the leading causes of deaths in women. Ovarian cancer is the second most diagnosed gynaecological malignancy and over all the fifth cause leading to death …
-
Binding and Signaling Differences between Prostaglandin E1 and E2 Mediated by Prostaglandin E Subtype Receptors
… by LC/MS analysis. A new mouse model of cancer was developed by subcutaneous injection of these cells into Balb/c/nu/nu mice. A 100% (8 out 8) occurrence rate of cancer mass was detected in these cells. In contrast, 30% occurrence of cancer mass were determined for the groups of the cells …
-
The development of 3-(4-hydroxyphenyl)indoline-2-ones and other strategies for the treatment of cancer
Submission published under a 24 month embargo labeled 'Closed Access', the embargo will last until 2024-05-01
-
Identifying new actions of estrogen receptor targetable with small molecules
… proliferation and metastatic potential of breast cancers, and likely some ovarian, endometrial, and cervical cancers. Endocrine therapy targeting these cancers often leads to development of resistance. Ovarian cancers do not respond to endocrine therapy. The presence of ERα in many resistant …